Endo Says FTC Is Forum-Shopping, Opposes Dismissal of Pay-for-Delay Suit

Endo Pharmaceuticals is pushing to keep alive a lawsuit against it by the Federal Trade Commission in the U.S. District Court for the Eastern District of Pennsylvania.

In its lawsuit the FTC claims that generic competition for the pain relief patch Lidoderm was delayed because of an illegal deal in 2012 involving Endo, generics maker Allergan’s Watson Laboratories and Teikoku Seiyaku, the company that supplies Lidoderm to Endo under a licensing agreement.

Endo is arguing that the FTC is only seeking dismissal of its suit so it can file it in another state where its chances of winning are better.